Controversial dwarfism drug, after clearing pivotal study, heads to the FDA

Controversial dwarfism drug, after clearing pivotal study, heads to the FDA

A controversial dwarfism drug, after clearing pivotal study, heads to the FDA

By DAMIAN GARDE

LAURA MORTON FOR STAT

BioMarin's treatment for the most common cause of dwarfism, achondroplasia, met its goal of increasing height in a pivotal study.

READ MORE